TerrAscend (TSNDF) Cash from Discontinued Operations (2022 - 2026)
TerrAscend (TSNDF) posted quarterly Cash from Discontinued Operations of 165000.0 for Q1 2026, up 94.8% year-over-year from 84701.6 in Q1 2025, and up 47.28% quarter-over-quarter from 313000.0 in Q4 2025.
TerrAscend (TSNDF) Cash from Discontinued Operations (2022 - 2026) Analysis & Trends
TerrAscend (TSNDF) has reported Cash from Discontinued Operations for 5 consecutive years, with 165000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Discontinued Operations rose 94.8% year-over-year to 165000.0; the TTM figure through Mar 2026 stood at 9389000.0 (up 17.93% YoY), while the FY2025 annual figure was 12398000.0, down 49.99% from the prior year.
- Cash from Discontinued Operations rose to 165000.0 in Q1 2026 per TSNDF's latest filing, from 313000.0 in the prior quarter.
- Across five years, Cash from Discontinued Operations topped out at 2956000.0 in Q4 2024 and bottomed at 20757000.0 in Q4 2023.
- Historically, Cash from Discontinued Operations has averaged 3095875.0 across 5 years, with a median of 1646500.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Discontinued Operations tumbled 9378.08% — and 2024, when it jumped 114.24%.
- TerrAscend's Cash from Discontinued Operations stood at 219000.0 in 2022, then sank by 9378.08% to 20757000.0 in 2023, then surged by 114.24% to 2956000.0 in 2024, then slumped by 110.59% to 313000.0 in 2025, then soared by 47.28% to 165000.0 in 2026.
- Business Quant data shows TSNDF's Cash from Discontinued Operations at 165000.0 in Q1 2026, 313000.0 in Q4 2025, and 4427000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | TerrAscend | 187.35 Mn | 145.23 Mn | 36.25 Mn | -806,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -806,000.00 |
| Jun 30, 2026 | -806,000.00 |
| Mar 31, 2026 | -165,000.00 |
| Mar 31, 2026 | -165,000.00 |
| Dec 31, 2025 | -313,000.00 |
| Dec 31, 2025 | -313,000.00 |
| Sep 30, 2025 | -4.43 Mn |
| Sep 30, 2025 | -4.43 Mn |
| Jun 30, 2025 | -4.48 Mn |
| Jun 30, 2025 | -4.48 Mn |
| Mar 31, 2025 | -3.17 Mn |
| Mar 31, 2025 | -3.17 Mn |
| Dec 31, 2024 | 2.96 Mn |
| Dec 31, 2024 | 2.96 Mn |
| Sep 30, 2024 | -4.05 Mn |
| Sep 30, 2024 | -4.05 Mn |
| Jun 30, 2024 | -7.18 Mn |
| Jun 30, 2024 | -7.18 Mn |
| Dec 31, 2023 | -20.76 Mn |
| Dec 31, 2023 | -20.76 Mn |